Abstract 3153: Prostatic acid phosphatase (PAP) predictive effect for prostate cancer in a population-based study: The renewal of PAP

Abstract

Abstract Objective: Use prostatic specific acid phosphatase (PAP) to characterize the disease progression and median survivals of patients with prostate cancer (PCa) based on the analysis in a population-based study from Surveillance, Epidemiology, and End Results (SEER) database. Materials and Methods: PCa patients with completed PAP results were selected from the SEER database of the National Cancer Institute. Mann-Whitney Sum test was utilized to compare the statistical significance for measurement data and ranked data, which were stratified by age, race, TNM Classification of Malignant Tumors (TNM), pathological grades, number of tumors, PAP and survival duration. Logistic analysis was performed to identify predictors of the presence of invasion and metastases. Cox regression was utilized to analyze the factors associated with all-cause mortality and prostate-cancer specific mortality. Moreover, survival curve was also present. Results: In total, there are 5184 PAP+ patients and 3161 PAP- patients involved in this study. The Mann-Whitney Sum test showed that slightly greater tumor size(p=0.03), elevated lymphatic (p=0.005) and distant (p<0.001) metastases rate, higher pathologic grade(p<0.001), localized tumor number (p<0.001), shortened survival months (p<0.001) were observed in the PAP+ group compared with the PAP- group. In the Multivariable Logistic Regression, invasion and metastases Hazard Ratio (HR) were elevated significantly (p<0.001) in the PAP+ individuals. In the survival analysis, PAP- patients experience the prolonged median survival. In the post-surgical patients, the survival months were still longer in PAP+ patients compared with the negative ones (p<0.001), though surgery prolonged the survival months of both groups. Survival months stratified by localized, invasion and metastases situations were analyzed. In the three stratified sub-groups, survival duration is significantly decreased in the PAP+ individuals in the localized PCa group (P<0.001**) and the metastases group (P=0.013). Conclusions: The findings of this study provide population-based estimates of the PCa progress and prognosis for patients with different PAP results, which may suggest a renewed period for the PAP. Citation Format: Fubo Wang, Huan Xu, Yinghao Sun. Prostatic acid phosphatase (PAP) predictive effect for prostate cancer in a population-based study: The renewal of PAP [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3153.